Klivira
Request demo

Optimizing Soliqua Prior Authorization for Rheumatology Practices

Klivira helps rheumatology practices navigate the complexities of prior authorization for medications like Soliqua, ensuring efficient patient access to necessary treatments. Our platform streamlines the Soliqua prior authorization for rheumatology patients, integrating seamlessly into existing workflows.

While Soliqua (insulin glargine and lixisenatide) is indicated for type 2 diabetes, rheumatology practices frequently manage patients with significant comorbidities, including metabolic conditions. The administrative burden of prior authorizations, even for non-rheumatology specific drugs, can strain resources. Klivira provides a robust solution to automate and simplify these processes, whether for primary rheumatology agents or critical comorbidity medications.

Understanding Soliqua's Role in Rheumatology Patient Management

Rheumatology patients often present with multiple comorbidities, and the management of conditions like type 2 diabetes is crucial for overall patient health, particularly given the potential for steroid-induced hyperglycemia. Soliqua, a high-volume prior authorization target across various payer types, may require PA for rheumatology patients, adding to the practice's administrative load. Klivira’s platform is designed to manage the diverse PA requirements for all medications encountered in a rheumatology setting, including those for comorbidities.

The Broader Prior Authorization Landscape in Rheumatology

Beyond specific comorbidity medications, rheumatology is a specialty with one of the highest prior authorization burdens due to the chronic nature of diseases and the cost of advanced agents. High-volume PA categories include biologics such as TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab) and non-TNF biologics (e.g., IL-6, IL-17, IL-23 inhibitors), as well as JAK inhibitors. Klivira addresses the full spectrum of these PA challenges.

Key Documentation Requirements for Rheumatology PAs

  • Diagnosis documentation: ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, ASAS for AS, 2019 EULAR/ACR for SLE).
  • Disease activity assessment: Objective scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
  • Prior conventional DMARD trial: Documentation of methotrexate, sulfasalazine, or other csDMARD trial and response, or contraindication.
  • Step therapy compliance: Proof of failure for required prior agents, often specific TNF inhibitors, before non-TNF biologics or JAK inhibitors.
  • Screening completion: TB screening (PPD or IGRA), hepatitis B/C screening, and immunization status prior to immunosuppressive biologic initiation.

Common Rheumatology PA Denial Reasons

  • Step therapy not completed: Failure to document the required sequence of prior agent trials.
  • Biosimilar substitution required: Denial of brand TNF inhibitor when a biosimilar should have been tried first.
  • Disease activity not documented: Missing objective scores like DAS28, CDAI, PASI, or equivalent.
  • Conservative-care duration insufficient: Initial csDMARD trial duration less than payer-required.
  • Screening documentation gaps: Incomplete TB, hepatitis, or immunization records.
  • Off-indication use without supporting policy: Request for a biologic outside its approved indication without specific payer policy support.

Klivira's Solution for Rheumatology Prior Authorization

Klivira’s platform is engineered to address the unique workflow constraints and documentation demands of rheumatology. Our system incorporates ACR-guideline-aware policy logic to streamline step therapy sequencing and biosimilar substitution routing based on specific payer mandates. We also manage the complexities of periodic re-authorizations for chronic treatments, including continuous response documentation, and correctly route medical-vs-pharmacy benefit splits for the same agent depending on administration mode and payer policy. This comprehensive approach reduces administrative burden and accelerates patient access to critical therapies.

Frequently asked questions

Why would Soliqua require prior authorization for a rheumatology patient?

While Soliqua is for type 2 diabetes, many rheumatology patients have this as a comorbidity, often exacerbated by disease or steroid use. Payers frequently require prior authorization for Soliqua to ensure medical necessity and adherence to clinical guidelines for diabetes management, even when prescribed by a rheumatologist managing overall patient care.

What are the main PA challenges for biologics in rheumatology?

Rheumatology biologics face challenges including complex step therapy requirements, variable biosimilar substitution policies across payers, stringent documentation for disease activity and diagnosis criteria, and the ongoing burden of periodic re-authorizations for chronic conditions. Klivira's platform is designed to navigate these specific complexities.

How does Klivira handle step therapy requirements for rheumatology drugs?

Klivira integrates ACR-guideline-aware policy logic into its automation engine. This allows the platform to accurately sequence step therapy requirements per indication, identify when biosimilar substitution is mandated, and ensure all necessary prior agent trials are documented according to payer-specific rules before submission.

What role do ACR guidelines play in rheumatology prior authorizations?

The ACR Treatment Guidelines are a dominant framework for indication-specific treatment escalation in rheumatology. Payers commonly reference these guidelines for diagnosis criteria, disease activity thresholds, and step therapy sequencing. Klivira's platform incorporates this guideline awareness to optimize PA submissions and reduce denials.

Does Klivira support re-authorization workflows for chronic rheumatology treatments?

Yes, Klivira provides a dedicated workflow for periodic re-authorizations, which are typical for chronic rheumatology treatments like biologics. The platform facilitates the continuous documentation of disease response and adherence to ongoing criteria required by payers, ensuring timely renewal of approvals.

Related coverage

Other soliqua prior authorization by payer

Other soliqua prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo